Evidence map›Paper›PMID 39992389›Full record

Trial reportDie Anaesthesiologie2025

Frequency of rebound pain and related factors in a multimodal regimen including systemic dexamethasone and dexmedetomidine.

Funda Atar, Fatma Özkan Sipahioğlu, Filiz Karaca Akaslan, Eda Macit Aydın, Evginar Sezer, Derya Özkan

Abstract readObservational StudyClinical Trial
PubMed Publisher
In one paragraph

Trial report in Die Anaesthesiologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Funda AtarDepartment of Anesthesiology and Reanimation, University of Health Sciences, Etlik City Hospital, 06100, Ankara, Turkey. fundaatar81@gmail.com.ORCID 0000-0002-3534-2233
Fatma Özkan SipahioğluDepartment of Anesthesiology and Reanimation, University of Health Sciences, Etlik City Hospital, 06100, Ankara, Turkey.ORCID 0000-0002-9350-2653
Filiz Karaca AkaslanDepartment of Anesthesiology and Reanimation, University of Health Sciences, Etlik City Hospital, 06100, Ankara, Turkey.ORCID 0000-0001-7767-9929
Eda Macit AydınDepartment of Anesthesiology and Reanimation, University of Health Sciences, Etlik City Hospital, 06100, Ankara, Turkey.ORCID 0000-0002-4607-4932
Evginar SezerDepartment of Anesthesiology and Reanimation, University of Health Sciences, Dışkapı Yıldırım Beyazıt Research and Training Hospital, Ankara, Turkey.ORCID 0000-0002-5858-7401
Derya ÖzkanDepartment of Anesthesiology and Reanimation, University of Health Sciences, Etlik City Hospital, 06100, Ankara, Turkey.ORCID 0000-0002-8964-3015

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis prospective observational study aimed to explore the frequency and risk factors of rebound pain (RP) in patients treated with multimodal analgesia and intravenous dexamethasone following a peripheral nerve block (PNB). MATERIAL AND

methodsAll patients who received preoperative PNB were given a standard multimodal analgesia regimen and intravenous dexamethasone. Motor and sensory block durations, RP severity and frequency were measured for the first 24 h post-PNB using a semistructured questionnaire. The RP was identified as acute postoperative pain within the first 12-24 h after sensory blockade resolution. The severity of RP was determined through the rebound pain score. Contributing risk factors to the development of RP were investigated.

resultsAfter the PNB had worn off RP developed in 27.7%. The following were identified as independent risk factors for RP: patient age, with an adjusted odds ratio (AOR) of 2.3 and a 95% confidence interval (CI) of 1.4-3.9, the use of bupivacaine in combination with lidocaine or prilocaine (AOR: 2.1, 95% CI 1.2-3.8), preoperative pain (AOR: 2.8, 95% CI 1.3-5.6), bone surgery (AOR: 1.8, 95% CI 1.0-3.0) and the duration of the surgery (AOR: 2.8, 95% CI 1.5-5.1).

conclusionAn exact identification of risk factors for RP can aid in creating preventative strategies that target changeable elements. A comprehensive understanding of this occurrence by PNB practitioners can lead to more effective use of PNB, decreased RP instances and improved outcome optimization.

Indexed as

DexamethasoneDexmedetomidinePostoperative PainAdultAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedNerve BlockPain MeasurementProspective StudiesRisk FactorsDexamethasoneDexmedetomidineOrthopedic surgeryPain managementPeripheral nerve blockPostoperative painRegional anesthesia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.